Transport by unmanned aerial systems (UASs) (e.g., drones) could save time and personnel. Our study aimed to assess the effect of drone transportation on the clinical laboratory results of biological samples by examining its impact on pre-analytical and analytical processes. We performed a cross-sectional study of healthy volunteers from Sha’ar Menashe Mental Health Center between July and November 2022. Blood and urine samples were transferred to the central laboratory at Hillel Yaffe Medical Center. Overall, 40 healthcare workers aged 21–67 years (57.5% females) with a mean age of 45.8 (SD = 11.3) years from Sha’ar Menashe Mental Health Center were recruited in the study. There were no significant differences between transportation modes in the complete blood count levels. We found a significant difference between the transportation modes for GGT (p = 0.01) and PT (p = 0.04), despite the very similar mean results of these tests. In Bland–Altman plots, GGT and PT samples fell within the 95% limits of agreement and were indicated as not clinically relevant; however, glucose and LDH did not meet the 95% acceptance criterion and showed a potential clinical effect. There was full agreement between the two types of transportation for urine glucose, nitrites, and urine cultures. UAS transport is an appropriate method for maintaining the quality of most routine clinical laboratory specimens, similar to the routine procedure of using a vehicle. For the 34 biochemistry, hematology, and coagulation assay parameters, only glucose and LDH did not meet the 95% acceptance criterion and showed a potential clinical effect.

Background: Hemodialysis patients are particularly vulnerable to hepatitis B virus (HBV) due to immunosuppression and repeated vascular access. While universal childhood vaccination has reduced population-level HBV prevalence, dialysis units require tailored prevention and monitoring strategies. This study aimed to characterize HBV serologic profiles, evaluate immune responses, and assess the kinetics of antibody waning in a diverse hemodialysis population. Methods: We retrospectively analyzed 565 adult hemodialysis patients (2015–2024), assessing HBV seroprevalence, seroconversion, booster response, and antibody waning. Subgroup comparisons were made by ethnicity and birth cohort (pre- vs. post-1992 national vaccine rollout). Time-to-waning analyses were performed using Kaplan–Meier methods. Results: HBsAg and anti-HBc were positive in 4.1% and 31.7% of patients, respectively; 3.7% were HCV seropositive. No HBsAg seroconversions occurred, and 2.1% of initially anti-HBc-negative patients seroconverted. Among patients with isolated anti-HBc, 80.9% developed protective anti-HBs titers, and none became HBsAg- or HBV DNA-positive. Waning anti-HBs titers occurred in 67.5% (median: 7.3 months), with 87.4% demonstrating a serologic response following documented vaccine delivery. Patients born after 1992 showed higher isolated anti-HBs positivity and lower anti-HBc prevalence. Ethnic subgroup analysis showed higher exposure rates but similar booster response among minority patients. Conclusions: HBV serologic profiles in this hemodialysis cohort reflected the interplay of immunosuppression, vaccination practices, and evolving epidemiologic trends. Subgroups exhibited variable vaccine responses, differing patterns of antibody waning, and a low incidence of new infections. These findings support tailored, population-specific HBV monitoring and prevention strategies in dialysis care.